RxDoctor Payments Data

Kent Sasse, MD

Colon & Rectal Surgery · Reno, NVNPI 1538104443

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $31,370 of the $43,711 with a category attached, or 71.8%. Acell, Inc. accounts for 72.4% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2019 at $23,262 and has fallen 92.2% since, to $1,821 in 2025.

$43,711in general payments, 2019–2025

Across 144 payments — averaging $303.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acell, Inc.$32K
  • Baxter Healthcare$4K
  • Palette Life Sciences, Inc.$3K
  • Medtronic$2K
  • Teleflex LLC$857
  • Axonics, Inc.$397
  • plus $2K from 23 others
$17,156in research payments, 2019–2025

Across 3 payments — averaging $5718.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Axonics, Inc.$17K

What the payments were for

  • Consulting fees$3,6708%
  • Speaking & faculty fees$31,37072%
  • Travel & lodging$4,52810%
  • Food & beverage$4,1449%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few colon & rectal surgery providers in Nevadato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$113,132
Medicare patients
176
Services billed
431

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Omeprazole59$675
Enoxaparin Sodium15$655
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen20$618
Ondansetron OdtOndansetron20$607
Scopolamine16$391
Oxybutynin Chloride41$269
Oxycodone Hcl12$59
Tramadol Hcl12$24

Paid to pharmacies, not to this prescriber.

Other colon & rectal surgery in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →